United Therapeutics Corporation (UTHR) Shares are Down -7.18%

United Therapeutics Corporation (UTHR) : During the past 4 weeks, traders have been relatively bearish on United Therapeutics Corporation (UTHR), hence the stock is down -3.41% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -7.33% relative to the S&P 500. The 4-week change in the price of the stock is -3.93% and the stock has fallen -7.18% in the past 1 week.

The stock has recorded a 20-day Moving Average of 3.81% and the 50-Day Moving Average is 3.75%.The 200 Day SMA reached 2.95%


United Therapeutics Corporation (NASDAQ:UTHR): After opening at $115.84, the stock dipped to an intraday low of $114.38 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $118.36 and the buying power remained strong till the end. The stock closed at $118.08 for the day, a gain of 2.66% for the day session. The total traded volume was 738,654. The stocks close on the previous trading day was $118.08.

United Therapeutics Corporation (UTHR) : The highest short term price target forecast on United Therapeutics Corporation (UTHR) is $229 and the lowest target price is $95. A total of 8 equity analysts are currently covering the company. The average price of all the analysts is $134.63 with a standard deviation of $40.26.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.